SCHEMBL4772175

SCHEMBL4772175

CNc1ncc2cc(-c3c(C)ccc4c(Nc5ccc(C#N)cc5)ncnc34)ccc2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 8/20 0.60
BRAF P15056 5/20 0.60
KDR P35968 6/20 0.49
MAPK14 Q16539 6/20 0.49
TEK Q02763 2/20 0.46
ABCG2 Q9UNQ0 1/20 0.41
CLK1 P49759 1/20 0.39
EIF2AK3 Q9NZJ5 1/20 0.38
EIF2AK4 Q9P2K8 1/20 0.38
EGFR P00533 2/20 0.38
JAK3 P52333 4/20 0.37
JAK1 P23458 1/20 0.37
TTBK1 Q5TCY1 1/20 0.37
TTBK2 Q6IQ55 1/20 0.37
SYK P43405 1/20 0.37
MAPKAPK2 P49137 1/20 0.37
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773348 0.89 LCK (0.46) LCKBRAFKDRMAPK14TEK
SCHEMBL4765016 0.88 LCK (0.61) LCKBRAFKDRMAPK14TEK
SCHEMBL4763552 0.87 LCK (0.78) LCKBRAFKDRMAPK14TEK
SCHEMBL4768484 0.85 BRAF (0.59) LCKBRAFKDRMAPK14TEK
SCHEMBL11889409 0.83 LCK (0.56) LCKBRAFKDRMAPK14TEK
SCHEMBL11888972 0.83 LCK (0.56) LCKBRAFKDRMAPK14TEK
SCHEMBL4763359 0.82 LCK (0.56) LCKBRAFKDRMAPK14TEK
SCHEMBL4764961 0.82 BRAF (0.56) LCKBRAFKDRMAPK14TEK
SCHEMBL2264429 0.82 LCK (0.56) LCKBRAFKDRMAPK14TEK
SCHEMBL5471596 0.81 LCK (0.54) LCKBRAFKDRMAPK14TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2481729-A1 Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases Amgen Inc. (US) 2012-08-01 EP claimed
EP-1976836-A2 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES Amgen Inc. (US) 2008-10-08 EP claimed
US-20070185324-A1 Nitrogen-containing bicyclic heteroaryl compounds and methods of use AMGEN INC. 2007-08-09 US claimed
WO-2007076092-A2 NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC. (US) 2007-07-05 WO claimed
EP-1976836-B9 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC (US) 2013-02-06 EP disclosed
EP-1976836-B1 NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC (US) 2012-08-22 EP disclosed
EP-2481729-A1 Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases Amgen Inc. (US) 2012-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185324-A1 Nitrogen-containing bicyclic heteroaryl compounds and methods of use BRAF, NRAS, RAF1 LCK 392/4885BRAF 1/4885KDR 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.